Summary
22.72 -2.77(-10.87%)11/15/2024
DNTH (DNTH)
DNTH reported last earnings on 2024-11-07 after the market. An EPS of $-0.74 was observed compared to an estimated EPS of $-0.59, resulting in a surprise value of $-0.15. A revenue of $0 million was observed compared to an estimated revenue of $1 million, resulting in a surprise value of $-1 Million.
DNTH (DNTH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -10.87 | 3.69 | 9.46 | 145.48 | 0.00 | 0.00 | 0.00 | 99.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Buy |
| P/E | Strong Sell |
| P/B | Sell |
| Trading Data | ||
| Close | 22.72 | |
| Open | 25.55 | |
| High | 25.93 | |
| Low | 22.34 | |
| Volume | 365,308 | |
| Change | -2.77 | |
| Change % | -10.87 | |
| Avg Volume (20 Days) | 160,257 | |
| Volume/Avg Volume (20 Days) Ratio | 2.28 | |
| 52 Week Range | 0.00 - 0.00 | |
| Price vs 52 Week High | inf% | |
| Price vs 52 Week Low | inf% | |
| Range | -0.04 | |
| Gap Up/Down | -0.47 | |
Fundamentals | ||
| Market Capitalization (Mln) | 820 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
11/07 18:36 EST - zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
11/07 16:01 EST - globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24
11/04 07:00 EST - globenewswire.com
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's...
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's...
10/15 07:00 EST - globenewswire.com
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster...
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster...
10/09 04:50 EST - zacks.com
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
08/08 18:25 EST - zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago.
08/08 16:01 EST - globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating...
07/08 12:11 EST - zacks.com
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
06/28 11:30 EST - globenewswire.com
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster...
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster...
06/12 07:00 EST - globenewswire.com
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q'24 and planned initiation of a Phase 2 trial in Chronic...
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q'24 and planned initiation of a Phase 2 trial in Chronic...
05/30 16:30 EST - globenewswire.com
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in...
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in...
05/20 01:38 EST - https://www.defenseworld.net
Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH)
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.28) per...
Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH)
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.28) per...
05/09 16:01 EST - globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H'25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor Neuropathy (MMN) to initiate 2Q'24 and Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H'25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor Neuropathy (MMN) to initiate 2Q'24 and Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy...
05/08 16:30 EST - globenewswire.com
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in...
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in...
05/03 16:30 EST - globenewswire.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted...
04/11 07:30 EST - globenewswire.com
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation...
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation...
03/26 10:46 EST - zacks.com
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.
03/21 16:01 EST - globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1'24 with top-line results anticipated in 2H'25
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1'24 with top-line results anticipated in 2H'25
03/07 16:30 EST - globenewswire.com
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today...
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today...